GlassScriptPhysician profile
Gena M Borgman
NPI 1164700092
$3,730.97
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $601 · 2023: $2,013 · 2024: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,980 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,979.63 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $878.66 | 2022-2024 | |
| Janssen Biotech, INC. | $638.27 | 2022-2024 | Tremfya, Remicade, Stelara |
| Amgen INC. | $346.97 | 2022-2024 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $341.07 | 2022-2023 | Cimzia |
| Lilly USA, LLC | $178.37 | 2023-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $170.75 | 2022-2023 | Saphnelo |
| Aurinia Pharma U.S., INC. | $161.26 | 2023-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $141.53 | 2022-2024 | Benlysta |
| Janssen Scientific Affairs, LLC | $126.23 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $120.95 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $108.54 | 2024 | Arcalyst |
| Fresenius Kabi USA, LLC | $74.81 | 2023-2024 | Idacio |
| Genzyme Corporation | $74.30 | 2024 | |
| Horizon Therapeutics Plc | $66.80 | 2022-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.10 | 2023-2024 | Cyltezo, Ofev |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $60.32 | 2023-2024 | |
| Pfizer INC. | $52.67 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $32.03 | 2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $28.03 | 2024 | Orencia |
| Sandoz INC. | $24.38 | 2024 | Hyrimoz |
| Organon LLC | $23.40 | 2023 | Hadlima |
| Depuy Synthes Sales INC. | $20.53 | 2023 | Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gena Borgman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.